VTVT - vTv Therapeutics amends licensing deal with Huadong Pharmaceutical

In a regulatory filing, Vtv Therapeutics (VTVT) has disclosed an amendment to the license agreement it entered with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a domestic drug manufacturer in China.The deal signed in 2017 granted the Chinese company the exclusive rights to develop, manufacture, and commercialize vTv's GLP-1R agonist program in China, Hong Kong, and 12 other Asian countries (ex. Japan).Per the amendment as agreed by both parties, vTv is no longer obliged to sponsor and contribute up to $3.0 million in support of a Phase 2 multi-region clinical trial.It also lowers the total potential development and regulatory milestone payments of $25.0 million under the original agreement by $3.0 million.vTv Therapeutics highlighted its partnerships in the recent investor presentation.

For further details see:

vTv Therapeutics amends licensing deal with Huadong Pharmaceutical